[go: up one dir, main page]

CO4910117A1 - Composicion de administracion oral con liberacion controlada de al menos un analgesico - Google Patents

Composicion de administracion oral con liberacion controlada de al menos un analgesico

Info

Publication number
CO4910117A1
CO4910117A1 CO00002025A CO00002025A CO4910117A1 CO 4910117 A1 CO4910117 A1 CO 4910117A1 CO 00002025 A CO00002025 A CO 00002025A CO 00002025 A CO00002025 A CO 00002025A CO 4910117 A1 CO4910117 A1 CO 4910117A1
Authority
CO
Colombia
Prior art keywords
analgesic
oral administration
controlled release
administration composition
composition according
Prior art date
Application number
CO00002025A
Other languages
English (en)
Inventor
Johannes Bartholomaus
Jurgen Betzing
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of CO4910117A1 publication Critical patent/CO4910117A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición de administración oral con liberacióncontrolada de al menos un analgésico, CARACTERIZADA porque está constituida por microtabletas de ANDlt; 3 mm de diámetro.Composición según las reivindicaciones 1 ó 2 caracterizada porque el analgésico comprende por lo menos un opioide.Composición según una o varias de las reivindicaciones 1 a 5 caracterizada porque las microtabletas presentan el analgésico uniformemente distribuido en una matriz retardante.Composición según la reivindicación 6, caracterizada porque la matriz comprende al menos un polímero, una cera, un aceite, una grasa, un ácido graso, un alcohol graso o un éster correspondiente.
CO00002025A 1999-01-18 2000-01-17 Composicion de administracion oral con liberacion controlada de al menos un analgesico CO4910117A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19901683A DE19901683B4 (de) 1999-01-18 1999-01-18 Analgetikum mit kontrollierter Wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
CO4910117A1 true CO4910117A1 (es) 2000-04-24

Family

ID=7894562

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00002025A CO4910117A1 (es) 1999-01-18 2000-01-17 Composicion de administracion oral con liberacion controlada de al menos un analgesico

Country Status (17)

Country Link
EP (1) EP1020183A3 (es)
JP (1) JP2000212069A (es)
KR (1) KR20000071245A (es)
CN (1) CN1270028A (es)
AR (1) AR021934A1 (es)
AU (1) AU777330B2 (es)
CA (1) CA2295469A1 (es)
CO (1) CO4910117A1 (es)
DE (1) DE19901683B4 (es)
HU (1) HUP0000137A3 (es)
IL (1) IL134075A0 (es)
NZ (1) NZ502260A (es)
PE (1) PE20001453A1 (es)
PL (1) PL337868A1 (es)
RU (1) RU2244541C2 (es)
SK (1) SK652000A3 (es)
ZA (1) ZA200000171B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19901687B4 (de) * 1999-01-18 2006-06-01 Grünenthal GmbH Opioide Analgetika mit kontrollierter Wirkstofffreisetzung
SK285128B6 (sk) * 1999-12-28 2006-07-07 Zentiva, A. S. Liečivý prípravok s riadeným uvoľňovaním obsahujúci tramadol hydrochlorid a spôsob jeho prípravy
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
EP1392250A2 (en) * 2001-06-08 2004-03-03 Endo Pharmaceuticals Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
EP1479381A1 (en) * 2003-05-19 2004-11-24 Euro-Celtique S.A. Pharmaceutical dosage form comprising a solid solution
CN100336501C (zh) * 2003-08-06 2007-09-12 健乔信元医药生技股份有限公司 醋炎痛缓释性圆粒组成物及制备方法
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
BRPI0615860B8 (pt) 2005-09-09 2021-05-25 Labopharm Barbados Ltd composição farmacêutica de liberação prolongada monolítica sólida
US8202535B2 (en) * 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
DE102006006532B4 (de) * 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102008056312A1 (de) 2008-11-07 2010-05-12 Biogenerics Pharma Gmbh Verwendung von Mikrotabletten als Lebens-und Futtermittelzusatz
KR101378973B1 (ko) * 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
AU2018390826B2 (en) 2017-12-20 2024-09-12 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5138M (es) * 1966-01-26 1967-06-05
CA1341504C (en) * 1988-03-25 2006-04-11 Jun Akimitsu Substituted superconductive bi-sr-ca-cu oxide and bi-sr-ca-ln-cu oxide compositions
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
IT1243341B (it) * 1990-07-13 1994-06-10 Farcon Ag Composizione farmaceutica per uso orale a rilascio modificato di antiinfiammatori non steroidei
EP1442745A1 (en) * 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
ES2168290T3 (es) * 1993-11-23 2002-06-16 Euro Celtique Sa Metodo para preparar una composicion de liberacion sostenida.
ATE322892T1 (de) * 1997-07-02 2006-04-15 Euro Celtique Sa Stabilisierte tramadol formulierungen mit verzögerter freisetzung
US6156342A (en) * 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form

Also Published As

Publication number Publication date
AU1010700A (en) 2000-07-20
DE19901683B4 (de) 2005-07-21
RU2244541C2 (ru) 2005-01-20
HU0000137D0 (en) 2000-03-28
JP2000212069A (ja) 2000-08-02
PE20001453A1 (es) 2000-12-23
HUP0000137A3 (en) 2001-03-28
NZ502260A (en) 2002-02-01
ZA200000171B (en) 2000-08-07
EP1020183A2 (de) 2000-07-19
DE19901683A1 (de) 2000-07-20
KR20000071245A (ko) 2000-11-25
CA2295469A1 (en) 2000-07-18
IL134075A0 (en) 2001-04-30
HUP0000137A2 (hu) 2001-02-28
EP1020183A3 (de) 2000-09-20
AU777330B2 (en) 2004-10-14
SK652000A3 (en) 2000-08-14
CN1270028A (zh) 2000-10-18
AR021934A1 (es) 2002-09-04
PL337868A1 (en) 2000-07-31

Similar Documents

Publication Publication Date Title
CO4910117A1 (es) Composicion de administracion oral con liberacion controlada de al menos un analgesico
AR039379A1 (es) Matriz para la liberacion sostenida, invariable e independiente de compuestos activos
AR111679A2 (es) Formulación farmacéutica de liberación controlada, procesos, usos, método
HRP20030493B1 (en) Pharmaceutical preparation comprising an active dispersed on a matrix
BR0112073A (pt) Combinações terapêuticas de ácidos graxos
ES2174814T3 (es) Acidos grasos esenciales destinados en la prevencion de accidentes cardio-vasculares.
CO4700474A1 (es) Formulacion oral de 2-metil-tieno-benzodiacepina
DE69233130D1 (de) Kaubare zusammensetzung zur arzneimittelfreisetzung
DK1341528T3 (da) Hurtigtopløsende tablet omfattende en syrelabil aktiv bestanddel
AR099437A2 (es) Matriz para la liberación sostenida, invariable e independiente de compuestos activos
AR026968A1 (es) Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral
RS50298B (sr) Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina
DE602006000819D1 (de) Dipyridamol enthaltende Zusammensetzungen mit verlängerter Freisetzung und Verfahren zu deren Herstellung
BR0010454A (pt) Composição farmacêutica contendo ciclosporina
FR2845289B1 (fr) Spheroides, procede de preparation et compositions pharmaceutiques.
AR001765A1 (es) Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales
BRPI0512649A (pt) artigos moldados sólidos contendo substáncias ativas para uso externo no combate a parasitas em animais
BRPI0409918A (pt) composição farmacêutica na forma de um hidrogel para administração transdérmica de ingredientes ativos
AR044863A1 (es) Una composicion de confiteria que suministra agentes antiplaca a la cavidad oral
AR006082A1 (es) Formulaciones farmacéuticas de liberación prolongada, que contienen mizolastina
DK0991741T3 (da) Voksestere, som er beriget med omega-3-umættede fedtsyrer, deres fremstilling og anvendelse
UY27170A1 (es) Formulación de medicamento que contiene un agente agonista muscarínico
AR016483A1 (es) Utilizacion de un agente para la prevencion de una enfermedad de las encias
ECSP982720A (es) Formulacion que contiene un opioide en combinacion con un agonista adrenergico y su utilizacion como analgesico
PE20010521A1 (es) Formas de administracion oral con liberacion total controlada de sustancia activa, encontrandose una misma sustancia activa en forma de al menos dos sales distintas que en la forma de administracion se encuentran en estado solido y que presentan dife